Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing
innovative treatments for solid cancers, today announced the 18-month follow-up
results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in
patients with platinum-sensitive recurrent ovarian cancer and peritoneal
carcinomatosis. The trial was closed for recruitment at the end of 2023 and
patients are currently in long-term follow-up. 

In this trial, 10 patients received a single intraperitoneal dose of 7 MBq
Radspherin®. Oncoinvent reported 12-month data in November  2024, where only 1
out of the 10 receiving the selected dose had peritoneal recurrence. At the
18-month follow-up, no further patient had experienced recurrence. i.e., only
10% of patients treated have so far had a recurrence. In similar populations,
receiving best standard of care, it is expected that approximately 40% of
patients would have had disease recurrence at this time point , , . 

 "Ovarian cancer's characteristic peritoneal metastasis lead to frequent
recurrences despite a comprehensive treatment approach," commented Dr. Luis
Chiva, Principal Investigator and Director of Department of Obstetrics and
Gynecology, Clinica Universidad de Navarra, Spain. "I am proud to be part of a
study program exploring whether Radspherin® may become a novel therapy that can
prevent disease progression, offering hope for a better and longer life for my
patients." 

"These compelling results underscore Radspherin®'s potential to significantly
reduce peritoneal recurrence in ovarian cancer patients," said Øystein Soug, CEO
of Oncoinvent. "The data not only reinforce our confidence in Radspherin® but
also support its advancement in Phase 2 trials, including the ongoing randomized
controlled Phase 2 trial assessing progression-free survival in patients with
peritoneal metastasis from ovarian cancer."

To discuss these promising clinical results, provide an update on operations,
and discuss the ongoing Phase 2 trial, Oncoinvent has decided to move up its
Quarterly Update from the previously announced May 27 to April 30 at 11:00 CEST.


About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. Currently one Phase 1 trial, one Phase
1/2a trial and one randomized Phase 2 trial are ongoing in the US, UK and
Europe. Preliminary clinical efficacy data are highly encouraging, and no
serious toxicity or safety concerns have been reported to date. The Oncoinvent
team consists of approx. 30 employees and runs a state-of-the-art manufacturing
facility to produce drug products for clinical trials in Nydalen, Oslo.
Oncoinvent is listed on the Euronext Growth Oslo.

About Radspherin 
Radspherin® is an investigational radiopharmaceutical designed for the local
treatment of cancer that has spread to body cavities. It consists of billions of
calcium carbonate microparticles containing the radioactive material radium-224.
The mode of action is the decay of radium-224 emitting alpha-particles, a highly
potent form of ionizing radiation. Radspherin® is investigated in ongoing
clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal
cancer and it is administered intraperitoneally after surgical resection with
removal of all macroscopic tumors. 

Forward-Looking Statements
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These
forward-looking statements represent Oncoinvent's expectations as of the date of
this press release, and Oncoinvent disclaims any obligation to update the
forward-looking statements. These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual results to
differ materially, including with respect to whether the results of clinical or
other studies will support the use of our product offerings, the impact of
results of such studies, our expectations of the reliability, accuracy and
performance of our tests, or of the benefits of our tests and product offerings
to patients, providers and payers.

For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com 

Tore Kvam, Chief Financial Officer 
Email: kvam@oncoinvent.com